Yiling Pharma H1 2026 Revenue RMB4.08B, Net Profit RMB757M, Up 13.28%

On the evening of August 28, 2026, Yiling Pharmaceutical disclosed its 2026 semi-annual report. During the first half, the company achieved operating revenue of RMB4.075 billion, with net profit attributable to shareholders of the listed company reaching RMB757 million, up 13.28% year-on-year. Net profit excluding non-recurring gains and losses was RMB731 million, an increase of 13.99%. Net cash flow from operating activities amounted to RMB1.18 billion, up 41.79% year-on-year.

During the reporting period, the company's operating costs decreased by 7.89% compared with the same period in 2025. The comprehensive gross margin stood at 62.99%, up 5.9 percentage points year-on-year. The asset-liability ratio was 22.03%, with a current ratio of 2.20 and a quick ratio of 1.59. Revenue from cardiovascular and cerebrovascular products reached approximately RMB2.45 billion, up 24.81% year-on-year, with gross margin increasing by 5.86 percentage points. Revenue from second-line patented products grew 17.14% year-on-year, with gross margin up more than 10 percentage points.

During the reporting period, the company's R&D investment totaled RMB345 million, accounting for 8.47% of revenue. Since 2021, cumulative R&D investment has exceeded RMB4 billion. Three international standard evidence-based studies on Shensong Yangxin Capsules, Qili Qiangxin Capsules, and Jinlida Granules were selected for the "2026 High-Impact Research in International Traditional Chinese Medicine and Traditional Medicine." The TXL-CAP multicenter clinical study on Tongxinluo Capsules for intervention in coronary vulnerable plaques was published in the journal Signal Transduction and Targeted Therapy.

In terms of the pipeline, the company is developing multiple innovative traditional Chinese medicines targeting the endocrine, digestive, and major respiratory fields, with three products in the new drug application stage. Qilong Dingchuan Tablets received clinical approval during the reporting period and entered Phase II clinical trials. The chemical drug Class 1 new drug Benamineprofen Injection was approved for marketing in January 2026 for postoperative analgesia. XY03-EA tablets completed the Phase IIb clinical trial during the reporting period and entered Phase III clinical trials.

According to company announcements, six exclusive patented traditional Chinese medicine products—Tongxinluo Capsules, Shensong Yangxin Capsules, Qili Qiangxin Capsules, Lianhua Qingwen Capsules (Granules), Jinlida Granules, and Jieyu Chufan Capsules—were included in the National Essential Medicines List (2026 edition). Among them, Jieyu Chufan Capsules is the only Class 1.1 innovative traditional Chinese medicine newly added in this edition. The new list will take effect on September 1, 2026.